Compare CYD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | NRIX |
|---|---|---|
| Founded | 1951 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1998 | 2020 |
| Metric | CYD | NRIX |
|---|---|---|
| Price | $40.76 | $14.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $60.00 | $30.58 |
| AVG Volume (30 Days) | 251.6K | ★ 785.4K |
| Earning Date | 02-24-2026 | 04-07-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $15.94 | N/A |
| Revenue Next Year | $7.89 | $26.32 |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $12.66 | $8.18 |
| 52 Week High | $56.55 | $22.50 |
| Indicator | CYD | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 38.66 |
| Support Level | $40.53 | $11.34 |
| Resistance Level | $41.24 | $16.47 |
| Average True Range (ATR) | 1.92 | 0.79 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 48.64 | 30.88 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.